Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP, Germing U, Malcovati L.
Blood. 2023 Dec 28;142(26):2247-2257. doi: 10.1182/blood.2023020078.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M.
Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850.
Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment.
Acha P, Mallo M, Solé F.
Cancers (Basel). 2022 Nov 10;14(22):5531. doi: 10.3390/cancers14225531.
Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q).
Invernizzi R.
Haematologica. 2022 Oct 1;107(10):2285. doi: 10.3324/haematol.2022.281643.
Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients.
Azevedo RS, Belli C, Bassolli L, Ferri L, Perusini MA, Enrico A, Pereira T, Junior W, Buccheri V, Pinheiro RF, Magalhaes SM, Schuster S, Castelli JB, Traina F, Rocha V, Velloso E.
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e1-e6. doi: 10.1016/j.clml.2021.07.026. Epub 2021 Jul 25.
[Myelodysplastic syndrome classification].
Ghariani I, Braham N, Hassine M, Kortas M.
Ann Biol Clin (Paris). 2013 Mar-Apr;71(2):139-44. doi: 10.1684/abc.2013.0804.
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Jädersten M, Karsan A.
Haematologica. 2011 Feb;96(2):177-80. doi: 10.3324/haematol.2010.038281.
Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion.
Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al-Ali N, Xicoy B, Lopez F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Díaz Varela N, Platzbecker U, Haase DT, Díez-Campelo M, Della Porta MG, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D.
Blood. 2024 Jul 29:blood.2024023840. doi: 10.1182/blood.2024023840. Online ahead of print.
Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone.
Washington NR, Shippey EA, Osswald M.
Cureus. 2021 Nov 19;13(11):e19742. doi: 10.7759/cureus.19742. eCollection 2021 Nov.
Competitive evolved sub-clonal BCR::ABL1 and novel MSI2::PC fusion genes in myelodysplastic syndrome with isolated del(5q).
Zhang Y, Liu Y, Wang T, Wang H, Chen X, Cao P, Ma X, Liu M, Xu P, Bi H, Pan J, Jiang Y, Li X, Wang W, Liu H.
Hematol Oncol. 2023 Feb;41(1):178-181. doi: 10.1002/hon.3095. Epub 2022 Nov 1.
